Fundz
Real-time · AI · Cross-signal

Eric J. Daniels, M.D., MBA just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Eric J. Daniels, M.D., MBA's next role move, new team, and the deals that follow. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.
✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.
✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.
✕Clay enriches lists you built — No live signal of its own, no who or when.
✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.
Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Kiora Pharmaceuticals Announces Resignation of Chief Development Officer

PUBLIC · KPRXApr 02, 2026•2 months ago

Position

Chief Development Officer

Company

KIORA PHARMACEUTICALS

Eric J. Daniels, M.D., MBA
EncinitasHealthcare

Description

On April 1, 2026, Kiora Pharmaceuticals, Inc. announced that Eric J. Daniels, M.D., MBA, will resign from his position as Chief Development Officer effective April 17, 2026

Company Information

Company

KIORA PHARMACEUTICALS

Location

332 ENCINITAS BOULEVARD

Encinitas, California, United States

About

Kiora Pharmaceuticals, Inc. (Kiora) is an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases. Publicly-traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for KIORA PHARMACEUTICALS's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.